Status:
COMPLETED
Brugada Ablation of VF Substrate Ongoing MultiCenter Registry
Lead Sponsor:
Pacific Rim Electrophysiology Research Institute
Collaborating Sponsors:
University Hospital, Bordeaux
University of Tsukuba
Conditions:
Brugada Syndrome
Eligibility:
All Genders
18-80 years
Brief Summary
Current treatment of high-risk Brugada Syndrome (BrS) patients (pts) with recurrent VF is limited. Catheter ablation (CA) has been performed for BrS but a large study with long-term outcomes of CA in ...
Detailed Description
Brugada syndrome (BrS) patients who undergo BRS substrate ablations from tertiary centers for catheter ablations of complex arrhythmias from three continents - Asia, Europe and North America - are reg...
Eligibility Criteria
Inclusion
- Symptomatic Brugada Syndrome patients who had undergone catheter ablation of the arrhythmogenic substrates.
Exclusion
- Patients who will not commit to regular follow up.
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT04420078
Start Date
July 1 2017
End Date
December 1 2023
Last Update
November 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pacific Rim Electrophysiology Research Institute, Chulalongkorn University
Bangkok, Thailand